News

KYORIN Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo; President & CEO: Yutaka Ogihara,hereinafter, "KYORIN") and UBE Corporation (Head Office: Minato-ku, Tokyo; President: Yuki Nishida,hereinafter, "UBE") announce that they have entered into a license agreement for novel drug candidates discovered by UBE.
Under the terms of this agreement, KYORIN has obtained exclusive worldwide rights to develop, manufacture,and commercialize these candidates. Accordingly, KYORIN will make an upfront payment to UBE. In addition,UBE is also eligible to receive development milestone payments based on the progress of development and
approval, and commercial milestone payments upon the achievement of specific net sales targets. UBE will also receive royalties based on net sales.
KYORIN aims to create high-value new drugs that meet medical needs and focuses on pain, autoimmune disorders, and neuromuscular disease as its key strategic therapeutic areas for research and development.Meanwhile, UBE creates lead compounds based on compound designs backed by its advanced organic synthesis capabilities.
Through this agreement, by integrating the creative compounds generated by UBE with KYORIN's research and development expertise, both companies aim to deliver new treatment options as early as possible to patients for whom existing drugs do not provide sufficient relief.